Rohto Pharmaceutical Co (MEX:4527N) Cyclically Adjusted Revenue per Share: MXN134.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4527N Rohto Pharmaceutical Co Ltd MEX:4527N
85 GF Score
Price MXN305.75
GF Value MXN368.70
! 7 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Rohto Pharmaceutical Co MEX:4527N 85 Cyclically Adjusted Revenue per Share is MXN134.66 as of Mar. 2026. GuruFocus rates MEX:4527N with a GF Score™ of 85/100 and a GF Value™ of MXN368.70. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rohto Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was MXN43.705. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN134.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rohto Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Rohto Pharmaceutical Co was 9.50% per year. The lowest was 4.70% per year. And the median was 7.15% per year.

As of today (2026-09-05), Rohto Pharmaceutical Co's current stock price is MXN305.75. Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN134.66. Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Rohto Pharmaceutical Co  (MEX:4527N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=305.75/134.66
=2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.25 94.24 95.79 134.12 134.66

Rohto Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.26 125.72 121.92 134.66 0.00

MEX:4527N vs PG, CL, EL: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


MEX:4527N
85GF Score
Rohto Pharmaceutical Co Ltd MEX:4527N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rohto Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=43.705/112.7000*112.7000
=43.705

Current CPI (Mar. 2026) = 112.7000.

Rohto Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 25.333 98.100 29.103
201609 31.870 98.000 36.651
201612 31.120 98.400 35.643
201703 31.508 98.100 36.197
201706 25.574 98.500 29.261
201709 30.465 98.800 34.751
201712 34.630 99.400 39.264
201803 35.778 99.200 40.647
201806 31.710 99.200 36.025
201809 33.972 99.900 38.325
201812 36.309 99.700 41.043
201903 37.370 99.700 42.243
201906 32.514 99.800 36.717
201909 38.941 100.100 43.843
201912 36.000 100.500 40.370
202003 47.925 100.300 53.850
202006 36.358 99.900 41.016
202009 40.505 99.900 45.695
202012 39.046 99.300 44.315
202103 42.227 99.900 47.637
202106 33.442 99.500 37.879
202109 39.728 100.100 44.729
202112 41.741 100.100 46.995
202203 40.828 101.100 45.513
202206 34.304 101.800 37.977
202209 35.620 103.100 38.937
202212 41.652 104.100 45.093
202303 36.783 104.400 39.707
202306 32.426 105.200 34.738
202309 34.348 106.200 36.450
202312 37.769 106.800 39.855
202403 33.728 107.200 35.458
202406 34.680 108.200 36.122
202409 42.575 108.900 44.061
202412 51.448 110.700 52.378
202503 49.600 111.100 50.314
202506 47.271 111.700 47.694
202509 44.142 112.000 44.418
202512 43.929 113.000 43.812
202603 43.705 112.700 43.705

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN134.66 mean?
Rohto Pharmaceutical Co (MEX:4527N) has a Cyclically Adjusted Revenue per Share of MXN134.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors.
Is Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is MXN134.66. Overall, Rohto Pharmaceutical Co has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share of MXN134.66 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors. Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is MXN134.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (MEX:4527N) has a current Cyclically Adjusted Revenue per Share of MXN134.66. The stock's GF Value™ is MXN368.70, compared to a current price of MXN305.75 — trading 17.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN134.66. Rohto Pharmaceutical Co's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Rohto Pharmaceutical Co (MEX:4527N), the current Cyclically Adjusted Revenue per Share is MXN134.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rohto Pharmaceutical Co (MEX:4527N) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of MXN305.75 is trading 17.1% below its estimated GF Value™ of MXN368.70.

Key valuation signals for MEX:4527N:

  • Cyclically Adjusted Revenue per Share: MXN134.66
  • GF Value™: MXN368.70 vs. price of MXN305.75 (17.1% below fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the MEX:4527N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rohto Pharmaceutical Co Business Description

Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
85GF Score

Get the complete analysis for MEX:4527N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.75
Price
MXN368.70
GF Value